Gradient scaffolding and methods of producing the same

• US 20060121609A1
• Filed: 09/21/2005
• Published: 06/08/2006
• Est. Priority Date: 09/21/2004
• Status: Abandoned Application

• Current Assignee: Massachusetts Institute of Technology
• Original Assignee: Massachusetts Institute of Technology
• Inventors: Spector, Myron, Harley, Brendan, Yannas, Ioannis V., Gibson, Lorna J., Samouhos, Stephen, O'Brien, Fergal J., Brau, Ricardo R.
• Application Number:
  US11/230,918
• Publication Number:
  US 20060121609A1
• Time in Patent Office: Days
• US Class Current: 435/395
• CPC Class Codes: A61L 27/16 obtained by reactions only involving carbon-to-carbon unsaturated bonds
• CPC Class Codes: A61L 27/50 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: A61L 27/56 Porous materials, e.g. foams or sponges
• CPC Class Codes: C08L 23/06 Polyethene
• CPC Class Codes: C08L 5/00 Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
• CPC Class Codes: C12M 25/14 Scaffolds; Matrices in general C12N5/0068

Abstract

This invention relates to gradient scaffolds, methods of producing the same, and methods of use thereof, in particular for applications in tissue engineering, repair and regeneration. The gradient scaffolding includes, inter-alia, scaffolds, which are varied in terms of their pore diameter, chemical composition, crosslink density, or combinations thereof, throughout the scaffolding.

Claims

1. A solid, non-uniformly porous biocompatible gradient scaffold, comprising at least one synthetic or natural polymer, ceramic, metal, extracellular matrix protein or an analogue thereof.

3. The gradient scaffold of claim 1, wherein said extracellular matrix proteins comprise a collagen, a glycosaminoglycan, or a combination thereof.

4. The gradient scaffold of claim 3, wherein said glycosaminoglycan is a chondoitin sulfate.

6. The gradient scaffold of claim 1, wherein pores within said scaffold are of a non-uniform average diameter.

7. The gradient scaffold of claim 6, wherein the average diameter of said pores ranges from 0.001-500 μ

m

8. The gradient scaffold of claim 6, wherein said average diameter of said pores varies as a function of its spatial organization in said scaffold.

9. The gradient scaffold of claim 8, wherein said average diameter of said pores varies along an arbitrary axis of said scaffold.

10. The gradient scaffold of claim 1, wherein said scaffold comprises regions devoid of pores.

11. The gradient scaffold of claim 10, wherein said regions are impenetrable to molecules with a radius of gyration or effective diameter of at least 1000 Da in size.

12. The gradient scaffold of claim 6, wherein said scaffold varies in its average pore diameter, or pore size distribution, concentration of components, cross-link density, or a combination thereof.

13. The gradient scaffold of claim 1, wherein said scaffold is characterized by a progressively changing pore volume fraction, ranging from a pore fraction of 0 to 0.999.

14. The gradient scaffold of claim 1, wherein said scaffold varies along a desired direction in the concentration of its components, cross-link density, or a combination thereof.

15. The gradient scaffold of claim 1, wherein the concentration of said polymer in said scaffold varies as a function of its spatial organization in said scaffold.

16. The gradient scaffold of claim 15, wherein said concentration varies along a given direction in said scaffold.

17. The gradient scaffold of claim 1, wherein the crosslink density of said scaffold varies along a desired direction in said scaffold.

18. The gradient scaffold of claim 1, wherein said scaffold further comprises cells, growth factors, cytokines, hormones, or a combination thereof.

114. A method of organ or tissue engineering in a subject, comprising the step of implanting a scaffold of claim 1 in said subject.

115. The method of claim 114, further comprising the step of implanting cells in said subject.

116. The method of claim 115, wherein said cells are seeded on said scaffold.

117. The method of claim 115, wherein said cells are stein or progenitor cells.

118. The method of claim 114, further comprising the step of administering cytokines, growth factors, hormones or a combination thereof.

119. The method of claim 114, wherein the engineered organ or tissue is comprised of heterogeneous cell types.

120. The method of claim 114, wherein the engineered organ or tissue is a connector organ or tissue.

121. The method of claim 120, wherein said connector tissue is a tendon or ligament.

122. A method of organ or tissue repair or regeneration in a subject, comprising the step of implanting a scaffold of claim 1 in said subject.

2. (canceled)

5. (canceled)

19. A process for preparing a non-uniformly porous, solid, biocompatible gradient scaffold, comprising at least one extracellular matrix component or an analog thereof, comprising the steps of:

(a) Freeze-drying a solution of at least one extracellular matrix component or an analog thereof, under conditions producing a gradient in the freezing temperature; and

(b) Sublimating ice-crystals formed within the slurry in step (a), prior to achievement of thermal equilibrium during said freeze-drying;

Wherein ice-crystals are formed along a gradient as a function of the gradient freezing temperature, whereby sublimation of said ice-crystals results in the formation of pores arranged along said gradient.

20. The process of claim 19, wherein said extracellular matrix component comprises a collagen, a glycosaminoglycan, or a combination thereof.

21. The process of claim 20, wherein said glycosaminoglycan is a chondroitin sulfate.

23. The process of claim 19, wherein the average diameter of said pores formed ranges from 0.001-500 μ

m.

24. The process of claim 19, wherein said average diameter of said pores varies as a function of its spatial organization in said scaffold.

25. The process of claim 19, wherein said average diameter of said pores varies along an arbitrary axis of said scaffold.

26. The process of claim 19, further comprising the steps of moistening at least one region within said scaffold formed in step (b) and exposing the moistened region to drying, under appropriate conditions for conversion of liquid water to water vapor, such that exposing said moistened region to drying results in pore collapse in said region.

27. The process of claim 26, wherein said scaffold produced comprises regions devoid of pores.

28. The process of claim 26, wherein moistening said region is conducted such that following exposure to said drying, said regions devoid of pores assume a particular geometry or pattern.

30. The process of claim 19, further comprising the step of exposing the scaffold to a gradient of solutions, wherein said solutions are characterized by increasingly higher salt concentration.

31. The process of claim 30, wherein exposure to said salt results in selective solubilization of at least one extracellular matrix component in said scaffold.

32. The process of claim 30, wherein solubilization of said at least one extracellular matrix component increases as a function of increasing salt concentration.

33. The process of claim 30, wherein said salt concentration is in a range corresponding to an ionic strength of between 0.001 and 10.

34. The process of claim 30, wherein said salt is Na₂PO₄, NaCl or combinations thereof

35. The process of claim 30, wherein the scaffold is exposed to water.

36. The process of claim 35, wherein solubilization of said at least one extracellular matrix component increases as a function of increasing solvent concentration

37. The process of claim 19, further comprising the step of exposing the scaffold to a gradient of solutions, comprising solutions of increasing concentration of an enzyme, which degrades or solubilizes at least one extracellular matrix component

38. The process of claim 37, wherein solubilization or degradation of said at least one extracellular matrix component increases as a function of increasing enzyme concentration.

39. The process of claim 37, wherein said enzyme is a coil agenase, a glycosidase, or a combination thereof.

40. The process of claim 37, wherein said enzyme concentration is in a range between 0.001-500 U/ml

41. The process of claim 19, further comprising the step of exposing the scaffold to a temperature gradient

42. The process of claim 41, wherein said temperature gradient is a range between 25-200°

C.

43. The process of claim 41, wherein exposing said scaffold to said temperature gradient, results in the creation of a gradient in crosslink density in said scaffold.

44. The process of claim 19, further comprising the step of exposing the scaffold to a gradient of solutions, which are increased in their concentration of cross-linking agent.

45. The process of claim 44, wherein exposure to said cross-linking agent results in the creation of a gradient in crosslink density in said scaffold.

46. The process of claim 44, wherein said cross-linking agent is glutaraldehyde, formaldehyde, paraformaldehyde, formalin, (1 ethyl 3-(3dimethyl aminopropyl)carbodiimide (EDAC), or UV light, or a combination thereof.

47. A non-uniformly porous, solid, biocompatible gradient scaffold prepared according to the process of claim 19.

22. (canceled)

29. (canceled)

48-100. -100. (canceled)

101. A process for preparing a solid, porous biocompatible gradient scaffold, comprising at least one extracellular matrix components or analogs thereof, comprising the steps of:

(a) Preparing a solution of a graft copolymer of at least one extracellular matrix components or analogs thereof;

(b) Freeze-drying the solution in step (a) to yield a solid, porous scaffold of uniform composition; and

(c) Exposing the scaffold formed in step (b) to a temperature gradient

Wherein exposing said scaffold to said temperature gradient, results in the creation of a gradient in crosslink density in said scaffold, thereby producing a solid, porous biocompatible gradient scaffold.

102. The process of claim 101, wherein said extracellular matrix components comprise a collagen, a glycosaminoglycan, or a combination thereof.

103. The process of claim 101, wherein said glycosaminoglycan is a chondroitin sulfate.

104. The process of claim 101, wherein said temperature gradient is a range between 25-200°

C.

105. The process of claim 101, further comprising the step of exposing the scaffold to a gradient of solutions, which are increased in their concentration of cross-linking agent.

106. The process of claim 105, wherein exposure to said cross-linking agent results in the creation of a gradient in crosslink density in said scaffold.

107. The process of claim 105, wherein said cross-linking age is glutaraldehyde, (1 ethyl 3-(3dimethyl aminopropyl)carbodiimide (EDAC), formaldehyde, paraformaldehyde, UV light of intensity sufficient to induce crosslinking or a combination thereof.

108. A solid, biocompatible gradient scaffold, prepared according to the process of claim 101.

109. A process for preparing a solid, porous biocompatible gradient scaffold, comprising at least one extracellular matrix component or analogs thereof, comprising the steps of:

(d) Preparing a solution of a graft copolymer of one or more extracellular matrix components or analogs thereof;

(e) Freeze-drying the solution in step (a) to yield a solid, in porous scaffold of uniform composition; and

(f) Exposing the scaffold formed in step (b) to a gradient of solutions, which are increased in their concentration of cross-linking agent

Wherein exposing said scaffold to said gradient of solutions, which are increased in their concentration of cross-linking agent, results in the creation of a gradient in crosslink density said scaffold, thereby producing a solid, porous, biocompatible gradient scaffold.

110. The process of claim 109, wherein extracellular matrix components comprise a collagen, a glycosaminoglycan, or a combination thereof.

111. The process of claim 110, wherein said glycosaminoglycan is a chondroitin sulfate.

112. The process of claim 109, wherein said cross-linking agent is glutaraldehyde, (1 ethyl 3-(3dimethyl aminopropyl)carbodiimide (EDAC), formaldehyde, paraformaldehyde, UV light or a combination thereof.

113. A solid, biocompatible gradient scaffold, prepared according to the process of claim 109.

123-129. -129. (canceled)